NCT00739986

Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo

A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 152 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).

Conditions

• Crohn's Disease

Interventions

Type	Name	Description
DRUG	Semapimod	semapimod 60 mg IV x 1 day, placebo x 2 days
DRUG	Semapimod	Semapimod 60 mg IV x 3 days
DRUG	Placebo	placebo IV x 3 days

Timeline

• Start date: 2002-10-01
• Primary completion: 2004-06-01
• Completion: 2004-08-01
• First posted: 2008-08-22
• Last updated: 2023-11-09

Locations

28 sites across 5 countries: United States, Belgium, Germany, Israel, Netherlands